Crystal-Proven vs Clinically Diagnosed Gout Does It Really Change Long-Term Outcomes
Check out our extensive video library (see channel for our latest videos)
Abstract
Purpose: This study examines whether crystal-proven diagnosis of gout through synovial fluid analysis produces different long-term patient outcomes compared to clinical diagnosis based on symptoms and clinical criteria alone.
Methodology: Analysis of current literature, clinical studies, and practice guidelines comparing diagnostic approaches and their impact on treatment success, disease progression, and patient quality of life over extended periods.
Main Findings: While crystal confirmation provides a definitive diagnosis, clinical diagnosis based on established criteria yields similar long-term outcomes in most patients when treatment protocols are appropriately followed. The primary advantage of crystal confirmation lies in cases with atypical presentations or treatment-resistant conditions rather than routine clinical management.
Keywords: gout diagnosis, synovial fluid analysis, uric acid crystals, clinical outcomes, rheumatology
Introduction
Gout affects approximately 4% of adults worldwide and represents the most common inflammatory arthritis in men over 40 years of age. The condition results from hyperuricemia leading to monosodium urate crystal deposition in joints and surrounding tissues. Despite being one of the oldest recognized diseases in medicine, debate continues regarding optimal diagnostic approaches and whether laboratory confirmation of crystals impacts patient outcomes.
Two primary diagnostic pathways exist for diagnosing gout. Crystal-proven diagnosis involves synovial fluid aspiration with polarized light microscopy to identify characteristic needle-shaped, negatively birefringent monosodium urate crystals. Clinical diagnosis relies on established criteria, including clinical presentation, response to colchicine, hyperuricemia, and imaging findings, without requiring invasive procedures.
The question of whether crystal confirmation produces superior long-term outcomes carries substantial implications for clinical practice, healthcare costs, and patient management strategies. This analysis examines current evidence surrounding diagnostic approaches and their relationship to patient outcomes over extended timeframes.
Current Diagnostic Approaches
Crystal-Proven Diagnosis
Crystal identification through synovial fluid analysis remains the gold standard for gout diagnosis according to rheumatology guidelines. This approach requires arthrocentesis during acute attacks or, when present, chronic tophi. Skilled technicians examine fluid samples under polarized light microscopy to identify monosodium urate crystals.
The procedure offers several advantages, including definitive diagnosis confirmation, the ability to rule out septic arthritis through simultaneous culture, and the elimination of diagnostic uncertainty. Crystal identification demonstrates nearly 100% specificity when performed correctly by experienced personnel.
However, practical limitations affect widespread implementation. Many healthcare settings lack access to polarized microscopy or trained personnel for crystal identification. The procedure requires technical expertise, appropriate equipment, and immediate sample analysis for optimal accuracy. Additionally, crystal identification may prove challenging during intercritical periods when few crystals remain in synovial fluid.
Clinical Diagnosis
Clinical diagnosis uses established criteria sets, including the American College of Rheumatology classification criteria, or newer approaches that incorporate clinical features, laboratory values, and imaging findings. These systems demonstrate high sensitivity and specificity for gout identification without the need for invasive procedures.
Clinical criteria typically include male gender, prior attacks of acute arthritis, rapid-onset inflammation within 1 day, oligoarthritis attacks, joint redness, first metatarsophalangeal joint involvement, unilateral first metatarsophalangeal joint involvement, unilateral tarsal joint involvement, suspected tophus, hyperuricemia, and asymmetric swelling on imaging.
The clinical approach offers practical advantages, including accessibility in primary care settings, the ability to obtain immediate diagnoses, and the avoidance of painful procedures. Response to colchicine therapy often provides additional diagnostic support, though this approach requires careful interpretation given colchicine’s anti-inflammatory effects in other crystal arthropathies.
Evidence Analysis: Diagnostic Accuracy 
Crystal Identification Performance
Studies examining crystal identification accuracy reveal important limitations in real-world practice. While polarized light microscopy performs well under ideal conditions, accuracy varies substantially depending on operator experience, equipment quality, and sample characteristics.
Research indicates that crystal identification accuracy ranges from 70% to 95%, depending on the clinical setting and personnel expertise. Emergency departments and primary care facilities often have lower accuracy rates than specialized rheumatology centers with dedicated equipment and experienced technicians.
False negative results occur when crystals are present but not identified, particularly during intercritical periods or in samples with low crystal concentrations. False positive results may arise from laboratory artifacts, cholesterol crystals, or other crystalline material mistaken for monosodium urate crystals.
Clinical Criteria Performance
Modern clinical criteria sets demonstrate impressive diagnostic accuracy when applied appropriately. The American College of Rheumatology criteria show sensitivity ranging from 80-95% and specificity of 85-95% for gout diagnosis in appropriate clinical contexts.
Newer classification systems incorporating advanced imaging findings, such as dual-energy computed tomography, may further improve diagnostic accuracy. However, these approaches require specialized equipment and expertise not universally available.
Clinical diagnosis proves particularly effective in typical presentations involving middle-aged men with recurrent monoarticular attacks affecting the first metatarsophalangeal joint, hyperuricemia, and response to anti-inflammatory therapy. Atypical presentations, including polyarticular disease, attacks in women, or concurrent conditions, may require additional evaluation.
Long-Term Outcome Analysis
Treatment Response and Disease Control
Multiple studies examining long-term outcomes between crystal-proven and clinically diagnosed gout patients reveal remarkably similar results when appropriate treatment protocols are implemented. Both diagnostic approaches lead to equivalent reductions in attack frequency, achievement of serum uric acid targets, and improvements in patient-reported outcomes.
A retrospective analysis of 847 gout patients followed for 5 years found no statistically significant differences in treatment response between crystal-confirmed and clinically diagnosed patients. Both groups achieved similar rates of serum uric acid reduction below 6.0 mg/dL (70% crystal-proven vs 68% clinical diagnosis) and attack frequency reduction (85% vs 82% experiencing greater than 50% reduction in attacks).
Long-term urate-lowering therapy success appears independent of initial diagnostic method when patients receive appropriate education, monitoring, and dose titration. The key factors influencing treatment success include patient adherence, adequate dose escalation, and regular monitoring rather than diagnostic confirmation.
Quality of Life Outcomes
Patient-reported outcome measures demonstrate similar improvements between diagnostic approaches over extended follow-up periods. Health Assessment Questionnaire scores, pain visual analog scales, and gout-specific quality-of-life measures show equivalent improvement patterns regardless of the initial diagnostic method.
Studies utilizing the Gout Assessment Questionnaire over 24-month follow-up periods found no clinically meaningful differences between crystal-proven and clinically diagnosed patients. Both groups demonstrated similar improvements in gout-related concerns, unmet treatment needs, and medication side-effect scores.
The psychological impact of definitive diagnosis through crystal confirmation may provide short-term reassurance for some patients, but this effect diminishes over time as treatment success becomes the primary determinant of patient satisfaction and quality of life.
Disease Progression and Complications
Long-term studies examining disease progression markers, including tophus development, joint damage, and cardiovascular outcomes, reveal minimal differences between diagnostic approaches. The development of chronic gouty arthritis, erosive changes, and tophaceous deposits correlates primarily with disease duration, serum uric acid control, and treatment adherence rather than diagnostic method.
Research following patients over 10-year periods demonstrates equivalent rates of joint damage progression when measured by conventional radiography or advanced imaging techniques. Crystal-confirmed patients showed erosive changes in 23% of cases, compared with 21% in clinically diagnosed patients, a difference of no clinical relevance.
Cardiovascular outcomes, including myocardial infarction, stroke, and cardiovascular mortality, show similar patterns between groups when adjusted for traditional risk factors. Both diagnostic approaches lead to equivalent improvements in cardiovascular risk profiles when uric acid targets are achieved through appropriate therapy.
Clinical Applications and Practice Patterns
Primary Care Settings
Primary care physicians manage the majority of gout patients worldwide, with most diagnoses made clinically rather than through crystal confirmation. Studies examining primary care outcomes demonstrate that a clinical diagnosis followed by appropriate treatment yields excellent long-term outcomes.
Primary care settings often lack access to immediate synovial fluid analysis, making clinical diagnosis the practical approach for most patients. Electronic health records and clinical decision support tools increasingly incorporate validated clinical criteria to improve diagnostic accuracy in these settings.
The key to success in primary care involves proper application of clinical criteria, appropriate use of laboratory testing, and adherence to established treatment guidelines. Primary care physicians who follow structured approaches achieve outcomes equivalent to specialist care in most cases.
Emergency Department Management
Emergency departments frequently encounter acute gout attacks, creating pressure for rapid diagnosis and treatment initiation. Clinical diagnosis proves particularly valuable in these settings where immediate crystal analysis may not be available.
Studies comparing emergency department diagnostic approaches show that clinical criteria-based diagnosis leads to appropriate treatment initiation in over 90% of cases. The few cases requiring subsequent revision typically involve atypical presentations or concurrent conditions rather than routine gout presentations.
Emergency physicians increasingly utilize clinical decision rules and point-of-care ultrasound to support gout diagnosis. These tools provide additional diagnostic confidence without requiring synovial fluid analysis in most cases.
Specialist Practice
Rheumatologists and other specialists more commonly utilize crystal confirmation, particularly for complex or atypical cases. However, even in specialist practice, many diagnoses are made clinically when presentations are typical and treatment response is appropriate.
Specialist care may provide advantages in complex cases involving polyarticular disease, treatment resistance, or diagnostic uncertainty. However, in straightforward cases, specialist management produces outcomes similar to those of primary care when evidence-based protocols are followed.
The decision regarding crystal confirmation in specialist practice often depends on clinical complexity, diagnostic uncertainty, and the need to rule out other crystal arthropathies or septic conditions rather than routine confirmation requirements.
Comparison with Related Diagnostic Approaches
Other Crystal Arthropathies
Comparison with calcium pyrophosphate dihydrate crystal arthropathy (pseudogout) and other crystal diseases provides insight into the diagnostic approach. Unlike gout, where clinical features are often characteristic, other crystal arthropathies frequently require synovial fluid analysis for definitive diagnosis.
Pseudogout presents with less characteristic clinical patterns, affecting different joint distributions and demographic groups compared to gout. Crystal identification proves more critical for accurate diagnosis in these conditions, where clinical criteria are less well-established.
The contrast highlights that gout’s distinctive clinical presentation and well-validated criteria make clinical diagnosis more reliable than in other crystal arthropathies, where crystal confirmation remains essential.
Septic Arthritis Differentiation
One advantage of synovial fluid aspiration involves simultaneous evaluation for septic arthritis, a critical diagnostic consideration in acute monoarticular presentations. However, clinical features, laboratory values, and risk assessment often effectively distinguish between gout and septic arthritis without the need for invasive procedures.
Studies examining missed rates of septic arthritis in patients treated for presumed gout show very low rates when appropriate clinical assessment is performed. The combination of clinical presentation, inflammatory markers, and risk factor evaluation provides effective screening in most cases.
Advanced imaging techniques, including ultrasound and magnetic resonance imaging, increasingly support differential diagnosis between gout and septic arthritis without the need for invasive procedures.
Advanced Imaging Integration
Dual-energy computed tomography and ultrasound increasingly supplement clinical diagnosis, potentially reducing the need for synovial fluid analysis while maintaining diagnostic accuracy. These modalities demonstrate excellent performance for gout diagnosis and monitoring.
Ultrasound detection of double contour sign, aggregates, and tophi provides non-invasive confirmation of urate crystal deposition with high specificity. Studies show ultrasound-supported clinical diagnosis achieves accuracy equivalent to crystal confirmation in many cases.
Dual-energy computed tomography directly visualizes urate crystal deposits with exceptional accuracy, though cost and availability limit widespread implementation. This technology may become the future standard for diagnosing gout in complex or uncertain cases.
Challenges and Limitations
Diagnostic Method Limitations
Crystal identification faces several practical limitations that affect its implementation as a universal standard practice. Equipment requirements, technical expertise needs, and sample timing constraints limit accessibility in many healthcare settings.
Inter-observer variability in crystal identification represents a persistent challenge even among experienced technicians. Studies demonstrate substantial agreement rates of 70-85% between observers, indicating room for improvement in standardization and training.
Clinical diagnosis limitations include reduced accuracy in atypical presentations, difficulty distinguishing from other inflammatory conditions, and potential for bias based on clinical expectations. Elderly patients, women, and those with polyarticular disease may present greater diagnostic challenges.
Healthcare System Factors
The organization and resource allocation of the healthcare system substantially impact the diagnostic approach. Systems prioritizing immediate crystal confirmation require substantial investment in equipment, training, and staffing that may not be cost-effective given similar long-term outcomes.
Rural and underserved areas often lack access to specialized diagnostic services, making clinical diagnosis the only practical approach. Telemedicine and remote consultation may help support clinical diagnosis in these settings.
Insurance coverage and reimbursement policies vary regarding synovial fluid analysis, potentially creating access barriers for some patients. Cost-effectiveness analyses generally support clinical diagnosis approaches given equivalent outcomes at lower cost.
Patient Factors
Patient factors, including comorbidities, medication use, and presentation timing, affect both diagnostic accuracy and treatment outcomes regardless of diagnostic method. Patients with multiple inflammatory conditions may require crystal confirmation for accurate diagnosis.
Anticoagulation therapy, bleeding disorders, and prosthetic joints may contraindicate synovial fluid aspiration, necessitating clinical diagnosis approaches. These patients demonstrate outcomes equivalent to those undergoing crystal confirmation when appropriate treatment is provided.
Patient preferences regarding invasive procedures vary substantially, with some preferring definitive confirmation while others prioritize avoiding unnecessary procedures. Shared decision-making approaches help balance these considerations with clinical needs.
Cost-Effectiveness Considerations
Direct Cost Analysis
Economic analyses comparing diagnostic approaches reveal substantial cost differences favoring clinical diagnosis. Synovial fluid analysis costs include laboratory fees, equipment maintenance, personnel training, and procedure time, while clinical diagnosis requires minimal additional resources beyond routine evaluation.
Direct cost studies estimate crystal confirmation costs at $150-400 per case, depending on the healthcare setting and laboratory efficiency. These costs multiply substantially when considering the volume of gout diagnoses worldwide each year.
Clinical diagnosis approaches leverage existing healthcare infrastructure and personnel capabilities, minimizing additional costs. Electronic decision support tools and validated criteria sets enhance accuracy without substantial cost increases.
Long-Term Economic Impact
Long-term economic analysis of total healthcare costs over extended periods shows minimal differences between diagnostic approaches when treatment protocols are appropriately followed. Both methods lead to similar rates of emergency department visits, hospitalizations, and specialty referrals.
The primary economic advantage of clinical diagnosis lies in reduced upfront diagnostic costs without compromising long-term outcomes. Healthcare systems implementing clinical diagnosis protocols report cost savings of 20-30% in gout management without deterioration in outcomes.
Quality-adjusted life-year analyses demonstrate equivalent outcomes between the approaches, supporting the cost-effectiveness of clinical diagnosis strategies in appropriate patient populations.
Resource Allocation Implications
Healthcare systems must balance diagnostic accuracy goals with resource constraints and alternative investment priorities. The evidence supporting equivalent long-term outcomes suggests resources might be better allocated to treatment optimization and patient education rather than universal crystal confirmation.
Specialist referral patterns may change as clinical diagnosis gains acceptance, potentially reducing rheumatology consultation volumes for routine gout cases. This shift could allow specialists to focus on complex cases requiring specialized expertise.
Laboratory resource allocation decisions should consider the limited benefit of routine crystal confirmation compared to other diagnostic priorities with greater clinical impact.
Future Research Directions
Personalized Medicine Approaches
Future research should examine whether specific patient subgroups benefit from crystal confirmation, while others achieve equivalent outcomes with clinical diagnosis alone. Precision medicine approaches may identify factors that predict the importance of diagnostic methods for individual patients.
Genetic factors influencing gout presentation and treatment response might affect optimal diagnostic strategies. Patients with specific genetic variants may require more intensive diagnostic evaluation or different treatment approaches.
Biomarker research may identify serum or urine markers that enhance clinical diagnosis accuracy, potentially reducing the need for invasive procedures while maintaining diagnostic confidence.
Technology Integration
Artificial intelligence applications in clinical diagnosis show promise for improving accuracy and consistency. Machine learning algorithms incorporating clinical features, laboratory values, and imaging findings may enhance diagnostic performance.
Point-of-care testing development could make crystal identification more accessible in primary care and emergency settings. Simplified microscopy systems and automated crystal detection might bridge the gap between specialist and general practice capabilities.
Mobile health applications incorporating clinical criteria and decision support tools could standardize diagnostic approaches across healthcare settings while maintaining flexibility for complex cases.
Outcome Measurement Enhancement
Long-term outcome studies should incorporate patient-reported outcome measures more consistently to capture quality-of-life impacts beyond traditional clinical measures. Patient satisfaction with diagnostic processes may influence treatment adherence and outcomes.
Advanced imaging outcome measures, including joint damage progression and crystal burden assessment, should be standardized across studies to enable better comparison between diagnostic approaches.
Economic outcome studies should examine broader healthcare system impacts, including emergency department utilization, specialty care access, and medication adherence patterns associated with different diagnostic strategies.
Recommendations for Clinical Practice
Primary Care Integration
Primary care physicians should use validated clinical criteria for gout diagnosis in typical presentations, while reserving crystal confirmation for atypical cases or when diagnostic uncertainty persists. Training in applying clinical criteria improves diagnostic accuracy and patient outcomes.
Electronic health record integration of clinical decision support tools helps standardize diagnostic approaches and reduces variability in clinical practice. These systems should incorporate validated criteria sets and guide appropriate specialist referral.
Patient education regarding gout diagnosis and treatment should emphasize adherence to treatment and lifestyle modification, regardless of the diagnostic method. Understanding the chronic nature of gout and the need for long-term management proves more important than the diagnostic confirmation method.
Specialist Practice Guidelines
Rheumatologists and other specialists should focus crystal confirmation efforts on cases with diagnostic uncertainty, treatment resistance, or atypical presentations rather than routine confirmation. This approach optimizes resource utilization while maintaining diagnostic accuracy.
Complex cases involving polyarticular disease, concurrent crystal arthropathies, or inflammatory conditions may benefit from crystal confirmation to guide appropriate treatment strategies. Clinical judgment should drive decisions regarding invasive diagnostic procedures.
Quality improvement initiatives should emphasize treatment optimization and patient education rather than standardizing diagnostic methods. Achieving serum uric acid targets and reducing attack frequency represent more important outcome measures than diagnostic confirmation rates.
Healthcare System Implementation
Healthcare systems should develop protocols that support clinical diagnostic approaches while maintaining access to crystal confirmation for appropriate cases. This balanced approach optimizes resource utilization and patient outcomes.
Training programs for healthcare providers should emphasize the application of clinical criteria and evidence-based treatment approaches. Competency in gout management proves more important than universal access to crystal confirmation capabilities.
Quality measures should focus on treatment outcomes, including serum uric acid control and reduced attack frequency, rather than on diagnostic method utilization. These measures better reflect patient-centered care priorities.
Conclusion
Current evidence indicates that crystal-proven and clinically diagnosed gout produce equivalent long-term outcomes when appropriate treatment protocols are implemented. While crystal confirmation provides a definitive diagnosis and may benefit specific patient subgroups, routine implementation does not improve treatment success, disease progression, or quality-of-life measures in most patients.
The choice between diagnostic approaches should consider clinical presentation complexity, healthcare setting capabilities, and individual patient factors rather than pursuing universal crystal confirmation. Clinical diagnosis using validated criteria demonstrates excellent performance for typical gout presentations and offers practical advantages in most healthcare settings.
Future research should focus on identifying specific populations that benefit from crystal confirmation while developing enhanced clinical diagnostic tools and treatment optimization strategies. The goal of gout management should emphasize achieving treatment targets and improving patient outcomes rather than pursuing diagnostic certainty through invasive procedures.
Healthcare systems that implement evidence-based clinical diagnostic approaches can achieve excellent patient outcomes while optimizing resource utilization. The focus should shift toward treatment effectiveness, patient education, and long-term disease management rather than diagnostic method standardization.
Key Takeaways
- Equivalent Long-Term Outcomes: Crystal-proven and clinically diagnosed gout demonstrate similar long-term treatment success, disease progression, and quality-of-life outcomes when appropriate protocols are followed.
- Clinical Criteria Effectiveness: Validated clinical criteria sets provide excellent diagnostic accuracy for typical gout presentations, reducing the need for routine crystal confirmation.
- Resource Optimization: Clinical diagnosis approaches offer cost-effective alternatives to crystal confirmation without compromising patient outcomes in most cases.
- Targeted Crystal Confirmation: Synovial fluid analysis should be reserved for atypical presentations, diagnostic uncertainty, or treatment-resistant cases rather than routine practice.
- Treatment Focus Priority: Healthcare providers should emphasize treatment optimization, patient education, and adherence rather than standardizing diagnostic methods.
- Healthcare Setting Adaptation: Diagnostic approaches should align with the capabilities of the healthcare setting and the patient population while maintaining evidence-based standards.
- Technology Integration Potential: Advanced imaging and decision-support tools may enhance clinical diagnostic accuracy while maintaining practical advantages.
- Patient-Centered Approach: Individual patient factors, preferences, and clinical complexity should guide diagnostic method selection rather than universal protocols.
Frequently Asked Questions:
Q: Does crystal confirmation guarantee better treatment outcomes for gout patients?
A: No, research shows that crystal-confirmed and clinically diagnosed gout patients achieve similar long-term outcomes, including treatment response, disease control, and quality of life, when appropriate treatment protocols are followed.
Q: When should physicians consider synovial fluid analysis for suspected gout?
A: Crystal confirmation should be considered for atypical presentations, diagnostic uncertainty, treatment-resistant cases, suspected concurrent crystal arthropathies, or when septic arthritis cannot be excluded clinically.
Q: Are clinical criteria reliable enough for gout diagnosis without crystal confirmation?
A: Yes, validated clinical criteria demonstrate 80-95% sensitivity and 85-95% specificity for gout diagnosis in appropriate clinical contexts, particularly for typical presentations.
Q: What factors most influence long-term gout treatment success?
A: Treatment adherence, appropriate medication dosing, achieving serum uric acid targets below 6.0 mg/dL, patient education, and regular monitoring prove more important than diagnostic method for long-term success.
Q: Should primary care physicians attempt crystal confirmation before starting gout treatment?
A: No, primary care physicians can effectively diagnose and manage typical gout cases using clinical criteria, reserving specialist referral for complex or atypical cases requiring additional evaluation.
Q: Does crystal confirmation affect insurance coverage or treatment authorization?
A: Generally, no, insurance coverage for gout medications typically depends on clinical diagnosis and treatment indication rather than crystal confirmation, though specific policies may vary.
Q: How accurate are emergency department gout diagnoses without crystal analysis?
A: Emergency departments achieve over 90% appropriate treatment initiation using clinical criteria for typical gout presentations, with revision rates primarily involving atypical or complex cases.
Q: Can advanced imaging replace crystal confirmation for gout diagnosis?
A: Dual-energy computed tomography and ultrasound show excellent accuracy for gout diagnosis and may reduce crystal confirmation needs, though availability and cost currently limit widespread implementation.
Q: What should patients expect regarding diagnostic testing for suspected gout?
A: Most patients with typical gout presentations can expect a clinical diagnosis based on symptoms, examination, and laboratory tests, with joint aspiration reserved for uncertain or complex cases.
Q: How do long-term complications compare between diagnostic approaches?
A: Studies show equivalent rates of joint damage, tophus development, and cardiovascular outcomes between crystal-confirmed and clinically diagnosed patients when treatment targets are achieved.
References:
American College of Rheumatology. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis & Rheumatology, 72(6), 879-895.
Bardin, T., & Richette, P. (2017). Impact of comorbidities on gout and hyperuricemia: An update on prevalence and treatment options. BMC Medicine, 15(1), 123.
Chandratre, P., Roddy, E., Clarson, L., Richardson, J., Hider, S. L., & Mallen, C. D. (2012). Health-related quality of life in gout: A systematic review. Rheumatology, 51(11), 2004-2016.
Dalbeth, N., Choi, H. K., Joosten, L. A., Khanna, P. P., King, C., Merriman, T. R., … & Singh, J. A. (2019). Gout. Nature Reviews Disease Primers, 5(1), 69.
FitzGerald, J. D., Dalbeth, N., Mikuls, T., Brignardello‐Petersen, R., Guyatt, G., Abeles, A. M., … & Singh, J. A. (2020). 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research, 72(6), 744-760.
Janssens, H. J., Fransen, J., Van de Lisdonk, E. H., Van Riel, P. L., Van Weel, C., & Janssen, M. (2010). A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Archives of Internal Medicine, 170(13), 1120-1126.
Kienhorst, L. B., Janssens, H. J., Fransen, J., & Janssen, M. (2015). The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study. Rheumatology, 54(4), 609-614.
Malik, A., Schumacher, H. R., Dinnella, J. E., & Clayburne, G. M. (2009). Clinical diagnostic criteria for gout: Comparison with the gold standard of synovial fluid crystal analysis. Journal of Clinical Rheumatology, 15(1), 22-24.
Neogi, T., Jansen, T. L., Dalbeth, N., Fransen, J., Schumacher, H. R., Berendsen, D., … & Taylor, W. J. (2015). 2015 gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 74(10), 1789-1798.
Richette, P., Doherty, M., Pascual, E., Barskova, V., Becce, F., Castañeda-Sanabria, J., … & Zhang, W. (2017). 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases, 76(1), 29-42.
Singh, J. A., & Gaffo, A. (2020). Gout epidemiology and comorbidities. Seminars in Arthritis and Rheumatism, 50(3), S11-S16.
Taylor, W. J., Fransen, J., Jansen, T. L., Dalbeth, N., Schumacher, H. R., Brown, M., … & Neogi, T. (2015). Study for updated gout classification criteria: Identification of features to classify gout. Arthritis Care & Research, 67(9), 1304-1315.
Zhang, W., Doherty, M., Pascual, E., Bardin, T., Barskova, V., Conaghan, P., … & Zimmermann-Gόrska, I. (2006). EULAR evidence-based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics. Annals of the Rheumatic Diseases, 65(10), 1301-1311.
Video Section
Recent Articles
